AstraZeneca
AZN
1,142 hedge funds and large institutions have $33.8B invested in AstraZeneca in 2024 Q1 according to their latest regulatory filings, with 120 funds opening new positions, 481 increasing their positions, 342 reducing their positions, and 93 closing their positions.
41% more repeat investments, than reductions
Existing positions increased: 481 | Existing positions reduced: 342
29% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 93
1% more funds holding
Funds holding: 1,130 → 1,142 (+12)
2% more call options, than puts
Call options by funds: $480M | Put options by funds: $470M
1% more capital invested
Capital invested by funds: $33.4B → $33.8B (+$425M)
0.09% more ownership
Funds ownership: 15.97% → 16.06% (+0.09%)
15% less funds holding in top 10
Funds holding in top 10: 13 → 11 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$596M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$491M |
| 3 |
Morgan Stanley
New York
|
+$170M |
| 4 |
Millennium Management
New York
|
+$151M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$147M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GQG Partners
Ft. Lauderdale,
Florida
|
-$903M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$157M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
-$129M |
| 4 |
D.E. Shaw & Co
New York
|
-$103M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$93.2M |
AZN Hedge Fund Activity: Q1 2024 in Review
1,142 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q1 2024, worth a combined $33.8B — up 1.3% from $33.4B a quarter earlier.
Buyers outnumbered sellers: 120 funds opened new AZN positions and 93 closed out — a net gain of 27 holders — while 481 added to existing stakes and 342 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $596M. The largest seller was GQG Partners, cutting an estimated $903M.
- 1,142 institutional investors held AstraZeneca (AZN) as of Q1 2024, up from 1,130 in Q4 2023.
- Funds reported $33.8B of AstraZeneca stock for Q1 2024, up 1.3% quarter-over-quarter.
- 120 funds opened new AstraZeneca positions in Q1 2024 and 93 closed out, a net change of +27 holders.
- The largest AstraZeneca buyer in Q1 2024 was T. Rowe Price Associates, an estimated $596M added.
- The largest AstraZeneca seller in Q1 2024 was GQG Partners, an estimated $903M sold.
Based on aggregated 13F filings for Q1 2024.